- Home
- / Jerusalem Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Jerusalem Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$48.9 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.8M | 34.1M | 36.4M | 46.2M | 46.1M | 39.7M | 39.8M | 48.9M |
| Cost of goods sold | 14.9M | 15.7M | 18.6M | 20.9M | 20.4M | 16.5M | 17.2M | 19.2M |
| Gross profit | 16.1M | 18.8M | 17.9M | 25.3M | 26.5M | 23.1M | 22.6M | 29.7M |
| Gross profit margin, % | 52.2% | 55.3% | 49.3% | 54.7% | 57.4% | 58.3% | 56.7% | 60.7% |
| Operating expense total | 9.2M | 11.1M | 10.4M | 13.2M | 14.0M | 10.8M | 11.2M | 13.1M |
| Depreciation and amortization | 1.7M | 2.3M | 2.9M | 3.0M | 2.2M | 2.1M | 2.2M | 2.1M |
| EBITDA | 6.9M | 7.9M | 7.6M | 12.1M | 12.5M | 12.3M | 11.4M | 16.6M |
| EBITDA margin, % | 22.3% | 23.0% | 20.8% | 26.2% | 27.1% | 31.1% | 28.7% | 33.9% |
| EBIT | 5.2M | 5.5M | 4.3M | 8.5M | 9.9M | 10.2M | 8.6M | 14.1M |
| EBIT margin, % | 16.7% | 16.0% | 11.7% | 18.3% | 21.4% | 25.8% | 21.6% | 28.9% |
| Interest expense | 91.0K | 259.0K | 292.0K | 216.0K | 196.0K | 228.0K | 306.0K | 282.0K |
| Pre tax profit | 5.5M | 5.0M | 3.7M | 7.6M | 8.8M | 8.8M | 6.6M | 12.8M |
| Income tax expense | 112.0K | 17.0K | 73.0K | 1.4M | 1.8M | 1.8M | 1.6M | 2.6M |
| Net Income | 5.4M | 5.0M | 3.7M | 6.2M | 7.0M | 7.0M | 5.1M | 10.3M |